drugset

drugset / Trial / NCT01941004

Safety and Efficacy of Fingolimod in MS Patients in China

NCT01941004 ↗

Phase 3 Withdrawn Novartis Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the safety and efficacy of fingolimod 0.5mg vs. placebo in MS patients in China

Timeline

Start: 2014-06
Primary completion: 2017-05
Completion: 2017-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Fingolimod	Small molecule	0.5 mg	Oral

Indications